Quick Answer
HeartBeam, Inc. reported Research And Development Expense of $13.45 million for the year ending 2025.
- HeartBeam, Inc. showed an increase of +21.7% in Research And Development Expense from 2024 to 2025.
- This data is from HeartBeam, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $57.0 thousand | Q1 2021: $29.0 thousand | Q2 2021: $25.0 thousand | Q3 2021: $105.0 thousand | Q1 2022: $734.0 thousand | Q2 2022: $1.74 million | Q3 2022: $1.56 million | Q1 2023: $1.68 million | Q2 2023: $1.48 million | Q3 2023: $1.62 million | Q1 2024: $2.43 million | Q2 2024: $2.84 million | Q3 2024: $2.89 million | Q1 2025: $3.49 million | Q2 2025: $3.33 million | Q3 2025: $3.28 million.
- Over the full 6 years of available data (2020 to 2025), HeartBeam, Inc.'s Research And Development Expense has grown by 10,012.8%.
- Historical annual values: Fiscal year 2025: $13.45 million | Fiscal year 2024: $11.05 million | Fiscal year 2023: $6.80 million | Fiscal year 2022: $5.68 million | Fiscal year 2021: $255.0 thousand | Fiscal year 2020: $133.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: